Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul 22;13(15):3672.
doi: 10.3390/cancers13153672.

Oncolytic Virus Immunotherapy

Antonio Marchini  1   2 , Carolina S Ilkow  3   4 , Alan Melcher  5
Affiliations
Editorial

Oncolytic Virus Immunotherapy

Antonio Marchini et al. Cancers (Basel). .

Abstract

Oncolytic viruses (OVs) were originally developed as direct cytotoxic agents but have been increasingly recognised as a form of immunotherapy [...].

PubMed Disclaimer

Conflict of interest statement

A.M. (Antonio Marchini) is the inventor on several H-1PV-related patents/patent applications. No other conflict of interest are declared by the authors.

References

    1. Macedo N., Miller D.M., Haq R., Kaufman H.L. Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer. 2020;8 doi: 10.1136/jitc-2020-001486. - DOI - PMC - PubMed
    1. Andtbacka R.H., Kaufman H.L., Collichio F., Amatruda T., Senzer N., Chesney J., Delman K.A., Spitler L.E., Puzanov I., Agarwala S.S., et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma. J. Clin. Oncol. 2015;33:2780–2788. doi: 10.1200/JCO.2014.58.3377. - DOI - PubMed
    1. Chesney J., Puzanov I., Collichio F., Singh P., Milhem M.M., Glaspy J., Hamid O., Ross M., Friedlander P., Garbe C., et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination with Ipilimumab Versus Ipilimumab Alone in Patients with Advanced, Unresectable Melanoma. J. Clin. Oncol. 2018;36:1658–1667. doi: 10.1200/JCO.2017.73.7379. - DOI - PMC - PubMed
    1. Cloughesy T.F., Petrecca K., Walbert T., Butowski N., Salacz M., Perry J., Damek D., Bota D., Bettegowda C., Zhu J.J., et al. Effect of Vocimagene Amiretrorepvec in Combination with Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients with Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020;6:1939–1946. doi: 10.1001/jamaoncol.2020.3161. - DOI - PMC - PubMed
    1. Moehler M., Heo J., Lee H.C., Tak W.Y., Chao Y., Paik S.W., Yim H.J., Byun K.S., Baron A., Ungerechts G., et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: A randomized multicenter Phase IIb trial (TRAVERSE) Oncoimmunology. 2019;8:1615817. doi: 10.1080/2162402X.2019.1615817. - DOI - PMC - PubMed

Publication types

LinkOut - more resources